PepGen Inc. (NASDAQ: PEPG) is a Healthcare company (Biotechnology) with a market capitalization of $263M. The Maz Rating grades it against the other companies in its sector.
PepGen Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.80, PepGen Inc. trades at 2.8x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -58.2%, return on invested capital of -65.7% and a free cash flow yield of -21.8%. On the balance sheet: a debt-to-equity ratio of 0.15 and a current ratio of 8.70. Over the past 52 weeks the share price ranged from $1.31 to $7.80, with a beta of 2.01.
PepGen Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 5 Buy and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, PepGen Inc. (PEPG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 52.2% / 30% · Interest income / Revenue 100500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 52.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 100500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 52.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 100500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 4.37% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 83.9% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 100500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 82.0% / 33.33% · (Cash+Recv) / Total Assets 82.0% / 33.33% · Interest income / Revenue 100500000.0% / 5% | Fail |
No. As of September 2026, PepGen Inc. (PEPG) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. PepGen Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 100500000.0% of each dividend: PepGen Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.